Monnalisa delisting triggers 10-day voluntary buyback offer at EUR 0.6735 per share starting Oct. 12
Bitget2026/10/08 12:20Monnalisa shares were delisted from Euronext Growth Milan under a Borsa Italiana revocation effective Oct. 6, 2026. Jafin Due, Modamet to buy eligible shareholders’ stock at EUR 0.6735 per share, capped at EUR 900,000 total. Purchase window set for 10 open-market days from 8:30 a.m. Oct. 12, 2026 to 4:00 p.m. Oct. 23, 2026. All valid sell orders to settle on Oct. 29, 2026; allocations switch to pro-rata if submitted shares exceed the cap. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monnalisa S.p.A. published the original content used to generate this news brief on October 08, 2026, and is solely responsible for the information contained therein.
- Monnalisa shares were delisted from Euronext Growth Milan under a Borsa Italiana revocation effective Oct. 6, 2026.
- Jafin Due, Modamet to buy eligible shareholders’ stock at EUR 0.6735 per share, capped at EUR 900,000 total.
- Purchase window set for 10 open-market days from 8:30 a.m. Oct. 12, 2026 to 4:00 p.m. Oct. 23, 2026.
- All valid sell orders to settle on Oct. 29, 2026; allocations switch to pro-rata if submitted shares exceed the cap.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
